More Press Releases

View Older Stories View Newer Stories

May 23, 2024 05:06PM G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
May 23, 2024 05:05PM Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
May 23, 2024 05:05PM EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
May 23, 2024 05:05PM Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening
May 23, 2024 05:05PM FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (m
May 23, 2024 05:05PM NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:05PM Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
May 23, 2024 05:05PM Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Ann
May 23, 2024 05:05PM ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024
May 23, 2024 05:05PM Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel
May 23, 2024 05:05PM BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:05PM IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma
May 23, 2024 05:05PM Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the
May 23, 2024 05:05PM Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
May 23, 2024 05:05PM TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
May 23, 2024 05:05PM I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
May 23, 2024 05:05PM Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
May 23, 2024 05:05PM TelevisaUnivision Announces Pricing of $1.0 Billion Debt
May 23, 2024 05:05PM Elcora Announces Share Consolidation
May 23, 2024 05:05PM Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinica
May 23, 2024 05:04PM Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
May 23, 2024 05:04PM BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. Declares Distribution
May 23, 2024 05:03PM Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
May 23, 2024 05:02PM White House National Cyber Director Coker Discusses Cybersecurity Implementation Plan 2.0 at Conference Hosted by McCrary Institute for Cyber & Critical Infrastructure Security
May 23, 2024 05:02PM KBRA Assigns AAA Rating, Stable Outlook to the New Mexico Finance Authority State Transportation Revenue Refunding Bonds (State Transportation Commission - Senior Lien), Series 2024A
May 23, 2024 05:02PM Stellar Bancorp, Inc. Declares Quarterly Dividend and New Share Repurchase Program
May 23, 2024 05:00PM Sierra Madre Announces Francisco Correa as General Manager of La Guitarra Mine and Mill Complex, Grants Incentive Options
May 23, 2024 05:00PM Cleantek Industries Inc. Announces First Quarter 2024 Results
May 23, 2024 05:00PM Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 23, 2024 05:01PM Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meet
May 23, 2024 05:01PM Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First
May 23, 2024 05:01PM NMDP and CIBMTR to Present New, Promising Stem Cell Transplantation Trial Data using Mismatched, Unrelated Donors at 2024 ASCO Annual Meeting
May 23, 2024 05:01PM Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST
May 23, 2024 05:01PM HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 23, 2024 05:00PM Timbercreek Financial Declares May 2024 Dividend
May 23, 2024 05:00PM Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024 05:00PM Canadian Premium Sand Inc. Announces Second Quarter 2024 Results
May 23, 2024 05:00PM Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
May 23, 2024 05:00PM Iambic Therapeutics Announces Poster Presentation for IAM1363, a Clinical Stage Type II HER2 Inhibitor, at the 2024 ASCO Annual Meeting
May 23, 2024 05:00PM Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
May 23, 2024 05:00PM Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:00PM SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
May 23, 2024 05:00PM Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
May 23, 2024 05:00PM Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
May 23, 2024 05:00PM Abstract Published in ASCO 2024 Annual Meeting Book Showcases Validity of Belong.Life's Conversational AI Cancer Mentor 'Dave'
May 23, 2024 05:00PM Orca Bio to Present Positive Clinical Outcomes with Orca-T in Patients with AML at 2024 ASCO Annual Meeting
May 23, 2024 05:00PM Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:00PM Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
May 23, 2024 05:00PM City of Hope Researchers to Present Investigational Treatments for Colorectal, Kidney and Blood Cancers at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:00PM Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
View Newer Stories View Older Stories